Pharvaris studies of rare disease drug put on hold by FDA

Pharvaris studies of rare disease drug put on hold by FDA

Source: 
BioPharma Dive
snippet: 

Shares in Pharvaris plunged Monday after the Swiss biotechnology company revealed the Food and Drug Administration has suspended testing of its most advanced drug for the rare disease hereditary angioedema.